Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Predicted Functional Consequences of TP53 Alterations and Prognosis in TP53 -Mutated Mantle Cell Lymphoma

Manik Uppal, Erel Joffe, Kurt S. Bantilan, Gilles Salles, Jacob Soumerai, Andrew D. Zelenetz, Anita Kumar

Blood (2023) 142 (Supplement 1): 3006.

https://doi.org/10.1182/blood-2023-187599

Published: 2023

Journal Articles

Genomic Correlates of Radiosensitivity in Diffuse Large B Cell Lymphoma

Jennifer Ma, Reith R Sarkar, Manik Uppal, Neil Wijetunga, Gilles Salles, Erel Joffe, Brandon S. Imber, Joachim Yahalom

Blood (2023) 142 (Supplement 1): 6104.

https://doi.org/10.1182/blood-2023-190846

Published: 2023

Journal Articles

Genetic Alterations of Follicular Lymphoma Can Predict Response to Very Low Dose Radiotherapy

N. Ari Wijetunga, Emily Lebow, Alexander Chan, Beatrice Fregonese, Venkatraman Seshan, Carla Hajj, Gustav Cederquist, Harper Hubbeling, Jennifer Ma, Reith R Sarkar, Kathryn Tringale, Pallavi Galera, Erel Joffe, Ahmet Dogan, Hans-Guido Wendel, Andrew D. Zelenetz, Gilles Salles, Brandon S. Imber, Joachim Yahalom

Blood (2023) 142 (Supplement 1): 6099.

https://doi.org/10.1182/blood-2023-185338

Published: 2023

Journal Articles

LymphGen Classification of Diffuse Large B-Cell Lymphoma in a Cohort of Adolescent and Young Adult (AYA) Patients

Angelo Cabal, Menglei Zhu, Manik Uppal, Erel Joffe, Connie Lee Batlevi, Matthew J. Matasar, Michelle Okwali, Ahmet Dogan, Andrew D. Zelenetz, Gilles Salles, Niloufer Khan

Blood (2022) 140 (Supplement 1): 6392–6393.

https://doi.org/10.1182/blood-2022-162418

Published: 2022

Journal Articles

Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma

Neil Ari Wijetunga, Emily S. Lebow, Jisun Lee, Beatrice Fregonese, Kathryn R. Tringale, Harper Hubbeling, Reith Sarkar, Jennifer Ma, Venkatraman Seshan, Erel Joffe, Ahmet Dogan, Alexander Chan, Guido Wendel, Carla Hajj, Brandon S. Imber, Joachim Yahalom

Blood (2022) 140 (Supplement 1): 6413–6414.

https://doi.org/10.1182/blood-2022-169501

Published: 2022

Journal Articles

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

Blood (2021) 138 (Supplement 1): 2447.

https://doi.org/10.1182/blood-2021-154226

Published: 2021

Journal Articles

High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

Katharine Louise Lewis, Lasse H. Jakobsen, Diego Villa, Sabela Bobillo, Karin Ekstroem Smedby, Kerry J. Savage, Toby A. Eyre, Kate Cwynarski, Paris L Caporn, Joan Van Zyl, Magdalena Klanova, Marek Trněný, Robert Puckrin, Douglas A. Stewart, Mark J Bishton, Christopher P. Fox, Aung M Tun, Gita Thanarajasingam, Faouzi Djebbari, Erel Joffe, Sandra Eloranta, Sara Harrysson, Laurie H. Sehn, Seth M Maliske, Kittika Poonsombudlert, Xiao Guo, Greg Hapgood, Kate Manos, Eliza Hawkes, Jahanzaib Khwaja, Adrian Minson, Michael Dickinson, Andreas Kiesbye Øvlisen, Gareth P Gregory, Michael Gilbertson, Isaac T Streit, Hamish W Scott, Matthew Ku, Sanjay de Mel, Kar Ying Yong, Liu Xin, Mridula Mokoonlall, Dipti Talaulikar, Nicholas L McVilly, Anna Johnston, Matthew J Brunner, Priyanka A Pophali, Matthew J. Maurer, Tarec Christoffer El-Galaly, Chan Yoon Cheah

Blood (2021) 138 (Supplement 1): 181.

https://doi.org/10.1182/blood-2021-146737

Published: 2021

Journal Articles

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 183.

https://doi.org/10.1182/blood-2021-148302

Published: 2021

Journal Articles

Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade

Beatriz Wills, Laure Michaud, Heiko Schöder, Nivetha Ganesan, Craig H. Moskowitz, David J. Straus, Lorenzo Falchi, Matthew J. Matasar, Andrew D. Zelenetz, Erel Joffe, Gottfried von Keudell, Connie Lee Batlevi, Audrey Hamilton, Philip C Caron, Ariela Noy, Gilles Salles, Alison J. Moskowitz

Blood (2021) 138 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2021-153383

Published: 2021

Journal Articles

Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience

Blood (2021) 138 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2021-153171

Published: 2021

Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Blood (2021) 138 (Supplement 1): 3753.

https://doi.org/10.1182/blood-2021-150961

Published: 2021

Journal Articles

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV + ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

Bradley M. Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E Brammer, Tatyana A. Feldman, Marcelo Capra, Elizabeth A Brem, Santosh M Nair, Phillip Scheinberg, Juliana Pereira, Leyla Shune, Erel Joffe, Afton Katkov, Robert McRae, Ivor Royston, Lisa Rojkjaer, Pierluigi Porcu

Blood (2021) 138 (Supplement 1): 623.

https://doi.org/10.1182/blood-2021-152603

Published: 2021

Journal Articles

The Outcome of CLL Patients According to IGHV Mutational Status: An Israeli Perspective

Yotam Bronstein, Shai Levi, Shlomo Tsuriel, Yamit Shorer Arbel, Erel Joffe, Yair Herishanu

Blood (2021) 138 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2021-149545

Published: 2021

Journal Articles

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Blood (2021) 138 (Supplement 1): 2513.

https://doi.org/10.1182/blood-2021-151994

Published: 2021

Journal Articles

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2529.

https://doi.org/10.1182/blood-2021-147527

Published: 2021

Journal Articles

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu, Irit Avivi, Anat Aharon, Gabi Shefer, Shai Levi, Yotam Bronstein, Miguel Morales, Tomer Ziv, Yamit Shorer Arbel, Lydia Scarfò, Erel Joffe, Chava Perry, Paolo Ghia

Blood (2021) 137 (23): 3165–3173.

https://doi.org/10.1182/blood.2021011568

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

Blood (2021) 137 (1): 39–48.

https://doi.org/10.1182/blood.2020005112

Published: 2021

Includes: Supplemental data

Journal Articles

CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population

Paola Ghione, MD, Kurt S. Bantilan, MPH, Erel Joffe, MD MSc, M. Lia Palomba, MD, Ariela Noy, MD, Matthew J Matasar, MD, Philip Caron, MD PhD, Audrey Hamilton, MD, Paul A. Hamlin, MD, Anita Kumar, MD, Colette Owens, MD, Alison J. Moskowitz, MD, Lorenzo Falchi, MD, Gottfried von Keudell, MDPhD, Ildefonso Rodriguez-Rivera, MD, David J. Straus, MD, Steven M. Horwitz, MD, Ahmet Dogan, MD PhD, Andrew D Zelenetz, MD PhD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140757

Published: 2020

Journal Articles

Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-136489

Published: 2020

Journal Articles

A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Erel Joffe, MD MSc, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Monica Mead, MD BS, Daniel J. Landsburg, MD, Timothy S. Fenske, MD, Radhakrishnan Ramchandren, Praveen Ramakrishnan Geethakumari, MD MS, Alan Skarbnik, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD, Han W. Tun, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-140884

Published: 2020

NARROW

Predicted Functional Consequences of TP53 Alterations and Prognosis in TP53 -Mutated Mantle Cell Lymphoma

Genomic Correlates of Radiosensitivity in Diffuse Large B Cell Lymphoma

Genetic Alterations of Follicular Lymphoma Can Predict Response to Very Low Dose Radiotherapy

LymphGen Classification of Diffuse Large B-Cell Lymphoma in a Cohort of Adolescent and Young Adult (AYA) Patients

Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade

Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV + ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

The Outcome of CLL Patients According to IGHV Mutational Status: An Israeli Perspective

Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience

Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era

CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population

Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era

A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only